This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Santa Arrives! High Beta & Momentum ETFs to Tap the Rally
by Sweta Killa
With the Santa Claus rally, high-beta and high-momentum ETFs are expected to outperform in the seven-day period and are intriguing choices for a short spell.
High-Beta ETFs to Bet on Renewed Market Momentum
by Sweta Killa
High-beta ETFs seek to capitalize on consistent growth with market-beating returns.
7 High-Beta ETFs to Ride the Super-Bull Stock Market
by Sweta Killa
The S&P 500 has been hitting a series of record highs and rebounded about 83% from its bottom reached in March last year, representing the best start to the new bull market on record, per LPL data.
Buy High-Beta & Momentum ETFs to Follow J.P. Morgan's Vision
by Sanghamitra Saha
The chief investment officer at JPMorgan Asset Management Bob Michele does not see overvaluation in Wall Street and suggested investors to join the rally.
Ride Market Rally With High-Beta ETFs & Stocks
by Sweta Killa
While every corner of the market is enjoying this ascent, high-beta ETFs and stocks seem a perfect bet at present.
5 High Beta & Momentum ETFs to Tap the Santa Rally
by Sweta Killa
These ETFs are expected to outperform in the seven-day period and are intriguing choices for a short spell.
5 ETFs at the Forefront of the Latest Market Rally
by Sweta Killa
Wall Street has hit a series of record highs with the four indices - the S&P 500, the Dow Jones, the Nasdaq Composite and the small-cap Russell 2000 - closed at new highs for the first time since January 2018 at the same time.
ETFs to Play as Vaccine News Looks to Outdo Virus Fear
by Sanghamitra Saha
After almost a year-long wait, the month of November started delivering sweet surprises to investors in the form of back-to-back vaccine news.
Reasons to Bet on High Beta ETFs & Stocks
by Sweta Killa
The momentum was driven by a vaccine development, which is being viewed as "a beginning to the end" of the coronavirus pandemic, and the prospect of divided congress, which is considered favorable for the economy.
5 ETFs Up Double Digits in a Day on Vaccine Optimism
by Sanghamitra Saha
Wall Street soared on Nov 9 on news that Pfizer (PFE) and BioNTech (BNTX) vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial.